Ipsen given an adcomm date for palovarotene; Ambrx Biopharma looks to secure $75M in latest securities offering
Ipsen has been given an advisory committee date of June 28 for its resubmitted NDA for palovarotene as a potential treatment …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
